Clinical trial
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have…
NCT00118313 · Craig L Slingluff, Jr, Other · Completed
Key facts
| NCT number | NCT00118313 |
|---|---|
| Title | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma |
| Official title | Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma |
| Lead sponsor | Craig L Slingluff, Jr, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug, Procedure |
| Interventions | incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim, tetanus toxoid helper peptide, dimethyl sulfoxide, imiquimod, adjuvant therapy |
| Start date | Nov 4, 2004 |
| Primary completion | Jul 28, 2006 |
| Completion | Jul 28, 2006 |
| First posted | Jul 11, 2005 |
| Last update posted | Mar 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: